Business Wire

MDS Global Launches an AI-powered Marketing Decision Intelligence Platform “MDS DecisionAI” That Enables Telcos to Reduce Churn and Increase Revenues

Share

Today, MDS Global, a leading provider of converged B2B/B2C billing and BSS solutions, has launched MDS DecisionAI, a new marketing decision intelligence platform that leverages the power of artificial intelligence to provide the critical insight ambitious MNOs, MVNOs, sub-brands and fixed line operators need to grow and outperform the competition.

MDS DecisionAI provides a full suite of telecoms specific AI modules including forecasting, churn, propensity models, and marketing and media mix analysis, that will help brands to optimise their marketing and commercial strategy. It enables them to identify monetisation opportunities and blind spots so they can make interventions sooner.

As a result, operators will be able to maximise yield and revenue, for example by predicting churn and identifying a customer’s propensity to consider other products offered in a cross-sell campaign, or through better-informed proposition development.

As part of MDS Global’s commitment to driving profitable digital telcos, MDS DecisionAI’s SaaS model, makes it a highly flexible and affordable way to operationally deploy AI. This is particularly beneficial for operators, MVNOs and sub brands who haven’t been able to invest in AI in the past due to the complexity of implementation, high integration costs and lack of affordable expert skill. The model eliminates the need for complex, costly and lengthy implementation projects. Instead, it can be easily integrated into existing billing, CVM and digital channels, no matter the platform used. Operators can expect to be set up and reaping the benefits of making more informed strategic decisions within 60 days.

Decision intelligence tools are changing the shape of telecoms with reports of cases where operators have made multi-million-pound revenue improvements from a more reactive churn response, seen 25% increase on cross sell success rates, and 30% uplift in acquisition by reviewing marketing media spend.

John Burton, CEO of MDS Global, says MDS DecisionAI will democratise artificial intelligence and decision intelligence, and make it accessible to all, including small brands: “Only 5%1 of telcos have a full AI marketing and personalisation strategy that is delivering an ROI on expected growth and benefits. MDS DecisionAI is a game changer and makes the vision of becoming a profitable digital telco more achievable.”

“Using MDS DecisionAI will create more agile and successful operators almost overnight. The use of AI will help them make the right commercial and marketing spending decisions and make more informed decisions about when and how to adjust their strategy or invest in innovation.”

More information about how AI is changing the telco landscape and supporting digital telco strategies is available here. Operators can also request a demo here.

About MDS Global

MDS Global is a leading provider of converged B2B/B2C billing and BSS solutions to MNOs, MVNOs, MVNEs and fixed line telcos. We power our customers’ transition from connectivity providers to digital service providers with carrier-grade solutions that include our cloud monetisation platform, AI-powered marketing decision intelligence platform, eSIM, and self-care apps portals.

Our agile “No code” SaaS solutions enable communications service providers to drive profit growth, deliver delightful digital customer experiences and launch innovative services fast.

To find out more, visit www.mdsglobal.com or follow us on LinkedIn and Twitter .

1 Unlocking the value of personalization at scale for operators, McKinsey, February 2022

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MDS Global press contact
Corine Suscens
Head of Global Marketing
marketing@mdsglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TreviPay Launches Pay by Invoice for Issuers Enabled by Visa Credentials20.1.2026 14:00:00 EET | Press release

TreviPay announces the launch of its Pay by Invoice solution for Visa-issuing banks, enabling issuers to capture a greater share of the $58 trillion North American B2B payments market. Through this collaboration with Visa, a world leader in digital payments, TreviPay’s order-to-cash automation technology combines with Visa’s commercial payment capabilities to help issuers move fragmented B2B spend into strategic, issuer-financed, invoice-based transactions. A Murphy Research study, found 26% of corporate payments are still made with checks or rely on manual legacy ACH processes. The study also shows 78% of global B2B buyers need customization or control in their payments and invoicing workflows, with 61% preferring to pay on net terms. Pay by Invoice helps banks meet these expectations by providing suppliers with early payment (generally within two days of invoicing) while enabling buyers to settle on negotiated terms such as 30, 60, or 90 days. Both parties benefit from an automated,

Armis Helps Italian Grocery Retailer Multicedi Strengthen Cyber Resilience20.1.2026 14:00:00 EET | Press release

Armis, the cyber exposure management & security company, today announced that Multicedi, one of the leading grocery retail groups in Central and Southern Italy, is using Armis Centrix™, Armis’ Cyber Exposure Management Platform, to strengthen its cybersecurity posture. “Before introducing Armis, critical issues were addressed only when malfunctions or abnormal events had already occurred,” said Livio De Prisco, Director of Information Systems at Multicedi. “With Armis Centrix™, the approach has completely changed: rather than responding reactively, the company now has a real-time view of its entire device fleet and can manage it proactively. We can detect devices that have been added to the network, prioritize risks based on their criticality, and define action plans and budgets consistent with our operational and regulatory requirements.” In recent years, Multicedi launched a comprehensive digital transformation program to modernize its application landscape and infrastructure backbon

Cargill Wins 2026 BIG Innovation Award20.1.2026 14:00:00 EET | Press release

Cargill today announced it has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system. Cargill was honored in the Innovative Organizations category, alongside a cohort of 159 companies, products and leaders that are transforming industries through applied innovation and measurable real-world impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120109897/en/ Cargill has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system. The recognition highlights the breadth and depth of Cargill’s innovation strategy, including the company’s use of automation, robotics, artificial

Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer20.1.2026 14:00:00 EET | Press release

Agendia, Inc., a leader in precision oncology for breast cancer, today announced that the updated NCCN Clinical Practice Guidelines in Oncology1 (NCCN Guidelines®) now recognize that MammaPrint® + BluePrint® can help identify a subset of hormone receptor positive, HER2-negative (HR+/HER2–) early-stage breast cancer (EBC) patients most likely to benefit from anthracycline-based chemotherapy. “I am delighted that oncologists finally have a way to identify HR+/HER2- early breast cancer patients who will benefit from anthracycline therapy," said Joyce A. O’Shaughnessy, M.D., principal investigator for the FLEX Study. “I think the biologic rationale and the data underpinning the observation that High Risk 2 Luminal (by BluePrint) breast cancer patients benefit from anthracycline therapy are quite strong.” The updated NCCN Guidelines are based on a three-year analysis of outcomes from a cohort of 1261 HR+/HER2- EBC patients from the prospective, real-world FLEX Study (NCT03053193), which was

Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI20.1.2026 12:03:00 EET | Press release

Philip Morris International Inc. (NYSE: PM) today released a new white paper, “Human Cognition: The Next Frontier?”, inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the “superskill” of the future, driving progress in an era of human-machine collaboration. As AI automates routine tasks and augments knowledge work, PMI argues that nurturing and protecting cognitive capacity will be essential for organizations seeking to remain resilient and relevant. Where once technology often automated labor-intensive jobs in the quest to improve productivity, now, as intelligent systems take on more cognitive work, organizations must rethink how they develop and protect the human mind itself. “In our strategic shift toward a smoke-

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye